This study demonstrated heterogeneous antibody response to respiratory syncytial virus (RSV) vaccines among immunocompromised persons. In contrast to universal seroconversion and preF IgG fold rises greater than 10 in immunocompetent persons, approximately 40% of immunocompromised participants did not seroconvert or achieve a conservative neutralization threshold postvaccination.

Better neutralization was seen among RSVA-AS01E recipients, suggesting possible augmentation by the vaccine adjuvant.

Low antibody titers may indicate a role for additional vaccine doses to enhance immune response among immunocompromised persons.

Study limitations include the small convenience sample, absence of cellular data, and lack of correlations with vaccine effectiveness.

Read More